UK-BNO-230019. DOP: January 2023.
What is post-stroke spasticity (PSS)?
How is PSS defined & what are the key symptoms?
Identify & manage your PSS patients
How can you accurately recognise symptoms & classify PSS?
Quality of life
What is the burden of PSS on daily life?
Treatment
How to treat your patients with PSS?
PSS: post-stroke spasticity.
BOTOX® (botulinum toxin type A) is indicated for the treatment of focal spasticity including:5
- wrist and hand disability due to upper limb spasticity associated with stroke in adults
- ankle and foot disability due to lower limb spasticity associated with stroke in adults
References
- Allergan. Data on file. INT/0423/2016
- Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
- Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
- Allergan. Data on file. 014
- BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed October 2022
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on [email protected]
Date of preparation: October 2022. UK-BTX-220200.
